The immuno-oncology assay market is estimated to be valued at US$ 5.6 billion in 2024. The immuno-oncology assay market is predicted to rise at a CAGR of 12.4% from 2024 to 2034. The global immuno-oncology assay market is anticipated to reach US$ 18.1 billion by 2034.
The immuno-oncology assay market is experiencing rapid growth, driven by the increasing prevalence of cancer globally and advancements in cancer immunotherapy. Immuno-oncology assays are critical tools for diagnosing cancer, predicting patient responses to treatment, and monitoring therapeutic efficacy by assessing the immune system's interactions with cancer cells.
Technological advancements play a significant role in the market's growth, with next-generation sequencing (NGS), flow cytometry, PCR, and immunoassays continuously improving assay sensitivity, specificity, and multiplexing capabilities. These innovations enable the identification of novel biomarkers and the development of companion diagnostics for personalized cancer treatment strategies.
| Attributes | Key Insights |
|---|---|
| Estimated Market Size in 2024 | US$ 5.6 billion |
| Projected Market Value in 2034 | US$ 18.1 billion |
| Value-based CAGR from 2024 to 2034 | 12.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2019 to 2023, the immuno-oncology assay market experienced a CAGR of 15.4%. The approval of immune checkpoint inhibitors revolutionized cancer treatment, leading to a surge in immuno-oncology research and development.
The immuno-oncology assay market witnessed rapid growth, fueled by increasing investments in research and clinical trials. Technological advancements, such as next-generation sequencing and multiplexed immunoassays, improved assay sensitivity and specificity. Regulatory approvals for companion diagnostics further accelerated market expansion.
The immuno-oncology assay market is expected to evolve further, with a focus on predictive and prognostic biomarkers, early cancer detection, and monitoring of treatment responses. Strategic collaborations, regulatory support, and reimbursement policies will continue to shape market dynamics.
The immuno-oncology assay market is poised for significant growth in the coming years, driven by ongoing advancements in cancer research, therapeutic innovation, and the increasing adoption of personalized medicine approaches in oncology.
Projections indicate that the global immuno-oncology assay market is expected to experience a CAGR of 12.4% from 2024 to 2034.
| Historical CAGR from 2019 to 2023 | 15.4% |
|---|---|
| Forecast CAGR from 2024 to 2034 | 12.4% |
Principal Consultant
South Korea and Japan stand out as the top two revenue-generating countries, as indicated in the table provided. The government and private sector investments in cancer research and immunotherapy initiatives are significant drivers of market growth in South Korea.
Japanese pharmaceutical companies are at the forefront of developing immunotherapy drugs and companion diagnostics. Regulatory support and streamlined approval processes for diagnostic products contribute to market growth.
| Countries | Forecast CAGRs from 2024 to 2034 |
|---|---|
| The United States | 12.1% |
| The United Kingdom | 13.9% |
| China | 13.3% |
| Japan | 14.1% |
| South Korea | 15.2% |
The immune-oncology assay market in the United States is expected to expand at a CAGR of 12.1% by 2034. The United States is at the forefront of cancer immunotherapy research and development, with significant investments from both public and private sectors.
The approval and adoption of novel immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies, have propelled the demand for immuno-oncology assays to assess treatment efficacy and patient response.
The United States-based companies and research institutions are driving innovations in immuno-oncology assay technologies, including next-generation sequencing, flow cytometry, and multiplexed immunoassays. These technological advancements enhance assay sensitivity, specificity, and throughput, enabling comprehensive profiling of the tumor microenvironment and immune response.
The immune-oncology assay market in the United Kingdom is expected to expand at a CAGR of 13.9% by 2034. The United Kingdom is home to leading research institutions, universities, and biotechnology companies actively engaged in immuno-oncology research and development.
Collaborative efforts between academia, industry, and government agencies fuel innovation in assay technologies, biomarker discovery, and therapeutic development, driving market growth.
The United Kingdom is a significant hub for clinical trials evaluating immunotherapies across various cancer types. The adoption of immune checkpoint inhibitors, CAR-T cell therapies, and other immunotherapeutic agents in clinical practice is increasing, necessitating the use of immuno-oncology assays for patient selection, treatment monitoring, and outcome prediction.
China faces a significant burden of cancer, with increasing incidence rates due to factors such as aging population, lifestyle changes, and environmental pollution.
This high disease burden drives the demand for immuno-oncology assays for early detection, diagnosis, and treatment monitoring. United Kingdom. The immune-oncology assay market in China is expected to rise at a CAGR of 13.3% by 2034.
The Chinese government has prioritized cancer prevention, diagnosis, and treatment as part of its healthcare reforms. Initiatives to improve cancer care infrastructure, enhance access to innovative therapies, and promote research and development in oncology contribute to market growth.
Japan has a growing cancer burden due to factors such as the aging population, lifestyle changes, and environmental factors. The rising prevalence of cancer drives the demand for immuno-oncology assays for early detection, diagnosis, and treatment monitoring. The immune-oncology assay market in Japan is expected to expand at a CAGR of 14.1% by 2034.
Japan has a strong research and development infrastructure in oncology, with leading academic institutions, biotechnology companies, and healthcare centers engaged in cancer research.
The country's contributions to cancer immunotherapy research, including novel therapies and biomarker discovery, fuel the demand for immuno-oncology assays.
South Korea is actively involved in cancer immunotherapy research and development. The adoption of immune checkpoint inhibitors, CAR-T cell therapies, and other immunotherapeutic agents is increasing, driving the demand for immuno-oncology assays to assess treatment efficacy and patient response. The immune-oncology assay market in South Korea is expected to flourish at a CAGR of 15.2% by 2034.
South Korean companies are at the forefront of technological innovation in diagnostics and biotechnology. They are developing advanced immuno-oncology assay platforms, including next-generation sequencing, flow cytometry, and multiplexed immunoassays, to meet the evolving needs of cancer diagnosis and treatment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The below section shows the leading segment. The reagents and antibodies segment is to rise at a CAGR of 12.2% from 2024 to 2034. Based on technology, the checkpoint inhibitors segment is anticipated to hold a dominant share through 2034. It is set to exhibit a CAGR of 11.9% from 2024 to 2034.
| Category | CAGR from 2024 to 2034 |
|---|---|
| Reagents and Antibodies | 12.2% |
| Checkpoint Inhibitors | 11.9% |
Based on type, the Reagents and Antibodies segment is anticipated to proliferate at a CAGR of 12.2% from 2024 to 2034.
Reagents and antibodies are essential components of immuno-oncology assays, playing crucial roles in detecting specific biomarkers, antigens, or immune cell markers associated with cancer and immunotherapy response.
Reagents and antibodies are highly specific and sensitive, allowing for the accurate detection and quantification of targets of interest in complex biological samples, such as blood, tissue, or tumor specimens.
Many immuno-oncology assays require multiplexing, where multiple targets are detected simultaneously in a single assay. Reagents and antibodies with multiplexing capabilities enable comprehensive profiling of the immune response and tumor microenvironment, providing valuable insights for cancer diagnosis and treatment.
Based on technology, the checkpoint inhibitors segment is anticipated to rise at a CAGR of 11.9% from 2024 to 2034.
Checkpoint inhibitors have revolutionized cancer treatment by enhancing the body's immune response against cancer cells. These therapies block inhibitory checkpoints, such as PD-1/PD-L1 and CTLA-4, allowing the immune system to recognize and attack cancer cells more effectively.
Biomarkers such as PD-L1 expression levels have been identified as predictors of response to checkpoint inhibitor therapy. Immuno-oncology assays are used to measure these biomarkers, allowing clinicians to identify patients who are most likely to respond to checkpoint inhibitors and tailor treatment accordingly.
The growing number of clinical trials investigating checkpoint inhibitors and combination therapies underscores their importance in immuno-oncology research. Immuno-oncology assays play a crucial role in these trials by assessing biomarker expression, immune cell profiling, and treatment responses.
Collaboration with academic institutions, research organizations, and biotechnology companies enables market players to access complementary expertise, technologies, and resources.
Partnerships facilitate biomarker discovery and validation, clinical validation studies, and the development of companion diagnostics. Collaborations also enhance market penetration, accelerate product development, and mitigate development risks.
| Attributes | Details |
|---|---|
| Estimated Market Size in 2024 | US$ 5.6 billion |
| Projected Market Valuation in 2034 | US$ 18.1 billion |
| Value-based CAGR 2024 to 2034 | 12.4 % |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | Value in US$ billion |
| Key Regions Covered |
|
| Key Market Segments Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
As of 2024, the market for immune oncology assays is expected to be valued at US$ 5.6 billion.
By 2034, the market value of immuno-oncology assays is expected to reach US$ 18.1 billion.
From 2024 to 2034, the immuno-oncology assay market is expected to flourish at a CAGR of 12.4%
The reagent and antibodies segment is expected to rise at a CAGR of 12.2% from 2024 to 2034.
South Kore is likely the top-performing market, with a CAGR of 15.2%.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2024 to 2034
5.3.1. Reagents and Antibodies
5.3.2. Instruments
5.3.3. Software
5.3.4. Consumables and Accessories
5.4. Y-o-Y Growth Trend Analysis By Product, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Product, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Technology
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2024 to 2034
6.3.1. Checkpoint Inhibitors
6.3.2. Cytokines & Immunomodulators
6.3.3. Monoclonal Antibodies
6.3.4. Other Technologies
6.4. Y-o-Y Growth Trend Analysis By Technology, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Technology, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2024 to 2034
7.3.1. Melanoma
7.3.2. Colorectal Cancer
7.3.3. Lung Cancer
7.3.4. Other Cancers
7.4. Y-o-Y Growth Trend Analysis By Indication, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Indication, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-Users
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End-Users, 2019 to 2023
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-Users, 2024 to 2034
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Cancer Research Centers
8.4. Y-o-Y Growth Trend Analysis By End-Users, 2019 to 2023
8.5. Absolute $ Opportunity Analysis By End-Users, 2024 to 2034
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Million) Analysis By Application, 2019 to 2023
9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2024 to 2034
9.3.1. Research Applications
9.3.2. Clinical Diagnostics
9.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023
9.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
10.1. Introduction
10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
10.3.1. North America
10.3.2. Latin America
10.3.3. Western Europe
10.3.4. Eastern Europe
10.3.5. South Asia and Pacific
10.3.6. East Asia
10.3.7. Middle East and Africa
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. USA
11.2.1.2. Canada
11.2.2. By Product
11.2.3. By Technology
11.2.4. By Indication
11.2.5. By End-Users
11.2.6. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By Technology
11.3.4. By Indication
11.3.5. By End-Users
11.3.6. By Application
11.4. Key Takeaways
12. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Brazil
12.2.1.2. Mexico
12.2.1.3. Rest of Latin America
12.2.2. By Product
12.2.3. By Technology
12.2.4. By Indication
12.2.5. By End-Users
12.2.6. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By Technology
12.3.4. By Indication
12.3.5. By End-Users
12.3.6. By Application
12.4. Key Takeaways
13. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. Germany
13.2.1.2. UK
13.2.1.3. France
13.2.1.4. Spain
13.2.1.5. Italy
13.2.1.6. Rest of Western Europe
13.2.2. By Product
13.2.3. By Technology
13.2.4. By Indication
13.2.5. By End-Users
13.2.6. By Application
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product
13.3.3. By Technology
13.3.4. By Indication
13.3.5. By End-Users
13.3.6. By Application
13.4. Key Takeaways
14. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. Poland
14.2.1.2. Russia
14.2.1.3. Czech Republic
14.2.1.4. Romania
14.2.1.5. Rest of Eastern Europe
14.2.2. By Product
14.2.3. By Technology
14.2.4. By Indication
14.2.5. By End-Users
14.2.6. By Application
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product
14.3.3. By Technology
14.3.4. By Indication
14.3.5. By End-Users
14.3.6. By Application
14.4. Key Takeaways
15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. India
15.2.1.2. Bangladesh
15.2.1.3. Australia
15.2.1.4. New Zealand
15.2.1.5. Rest of South Asia and Pacific
15.2.2. By Product
15.2.3. By Technology
15.2.4. By Indication
15.2.5. By End-Users
15.2.6. By Application
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product
15.3.3. By Technology
15.3.4. By Indication
15.3.5. By End-Users
15.3.6. By Application
15.4. Key Takeaways
16. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
16.2.1. By Country
16.2.1.1. China
16.2.1.2. Japan
16.2.1.3. South Korea
16.2.2. By Product
16.2.3. By Technology
16.2.4. By Indication
16.2.5. By End-Users
16.2.6. By Application
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Product
16.3.3. By Technology
16.3.4. By Indication
16.3.5. By End-Users
16.3.6. By Application
16.4. Key Takeaways
17. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
17.2.1. By Country
17.2.1.1. GCC Countries
17.2.1.2. South Africa
17.2.1.3. Israel
17.2.1.4. Rest of MEA
17.2.2. By Product
17.2.3. By Technology
17.2.4. By Indication
17.2.5. By End-Users
17.2.6. By Application
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Product
17.3.3. By Technology
17.3.4. By Indication
17.3.5. By End-Users
17.3.6. By Application
17.4. Key Takeaways
18. Key Countries Market Analysis
18.1. USA
18.1.1. Pricing Analysis
18.1.2. Market Share Analysis, 2023
18.1.2.1. By Product
18.1.2.2. By Technology
18.1.2.3. By Indication
18.1.2.4. By End-Users
18.1.2.5. By Application
18.2. Canada
18.2.1. Pricing Analysis
18.2.2. Market Share Analysis, 2023
18.2.2.1. By Product
18.2.2.2. By Technology
18.2.2.3. By Indication
18.2.2.4. By End-Users
18.2.2.5. By Application
18.3. Brazil
18.3.1. Pricing Analysis
18.3.2. Market Share Analysis, 2023
18.3.2.1. By Product
18.3.2.2. By Technology
18.3.2.3. By Indication
18.3.2.4. By End-Users
18.3.2.5. By Application
18.4. Mexico
18.4.1. Pricing Analysis
18.4.2. Market Share Analysis, 2023
18.4.2.1. By Product
18.4.2.2. By Technology
18.4.2.3. By Indication
18.4.2.4. By End-Users
18.4.2.5. By Application
18.5. Germany
18.5.1. Pricing Analysis
18.5.2. Market Share Analysis, 2023
18.5.2.1. By Product
18.5.2.2. By Technology
18.5.2.3. By Indication
18.5.2.4. By End-Users
18.5.2.5. By Application
18.6. UK
18.6.1. Pricing Analysis
18.6.2. Market Share Analysis, 2023
18.6.2.1. By Product
18.6.2.2. By Technology
18.6.2.3. By Indication
18.6.2.4. By End-Users
18.6.2.5. By Application
18.7. France
18.7.1. Pricing Analysis
18.7.2. Market Share Analysis, 2023
18.7.2.1. By Product
18.7.2.2. By Technology
18.7.2.3. By Indication
18.7.2.4. By End-Users
18.7.2.5. By Application
18.8. Spain
18.8.1. Pricing Analysis
18.8.2. Market Share Analysis, 2023
18.8.2.1. By Product
18.8.2.2. By Technology
18.8.2.3. By Indication
18.8.2.4. By End-Users
18.8.2.5. By Application
18.9. Italy
18.9.1. Pricing Analysis
18.9.2. Market Share Analysis, 2023
18.9.2.1. By Product
18.9.2.2. By Technology
18.9.2.3. By Indication
18.9.2.4. By End-Users
18.9.2.5. By Application
18.10. Poland
18.10.1. Pricing Analysis
18.10.2. Market Share Analysis, 2023
18.10.2.1. By Product
18.10.2.2. By Technology
18.10.2.3. By Indication
18.10.2.4. By End-Users
18.10.2.5. By Application
18.11. Russia
18.11.1. Pricing Analysis
18.11.2. Market Share Analysis, 2023
18.11.2.1. By Product
18.11.2.2. By Technology
18.11.2.3. By Indication
18.11.2.4. By End-Users
18.11.2.5. By Application
18.12. Czech Republic
18.12.1. Pricing Analysis
18.12.2. Market Share Analysis, 2023
18.12.2.1. By Product
18.12.2.2. By Technology
18.12.2.3. By Indication
18.12.2.4. By End-Users
18.12.2.5. By Application
18.13. Romania
18.13.1. Pricing Analysis
18.13.2. Market Share Analysis, 2023
18.13.2.1. By Product
18.13.2.2. By Technology
18.13.2.3. By Indication
18.13.2.4. By End-Users
18.13.2.5. By Application
18.14. India
18.14.1. Pricing Analysis
18.14.2. Market Share Analysis, 2023
18.14.2.1. By Product
18.14.2.2. By Technology
18.14.2.3. By Indication
18.14.2.4. By End-Users
18.14.2.5. By Application
18.15. Bangladesh
18.15.1. Pricing Analysis
18.15.2. Market Share Analysis, 2023
18.15.2.1. By Product
18.15.2.2. By Technology
18.15.2.3. By Indication
18.15.2.4. By End-Users
18.15.2.5. By Application
18.16. Australia
18.16.1. Pricing Analysis
18.16.2. Market Share Analysis, 2023
18.16.2.1. By Product
18.16.2.2. By Technology
18.16.2.3. By Indication
18.16.2.4. By End-Users
18.16.2.5. By Application
18.17. New Zealand
18.17.1. Pricing Analysis
18.17.2. Market Share Analysis, 2023
18.17.2.1. By Product
18.17.2.2. By Technology
18.17.2.3. By Indication
18.17.2.4. By End-Users
18.17.2.5. By Application
18.18. China
18.18.1. Pricing Analysis
18.18.2. Market Share Analysis, 2023
18.18.2.1. By Product
18.18.2.2. By Technology
18.18.2.3. By Indication
18.18.2.4. By End-Users
18.18.2.5. By Application
18.19. Japan
18.19.1. Pricing Analysis
18.19.2. Market Share Analysis, 2023
18.19.2.1. By Product
18.19.2.2. By Technology
18.19.2.3. By Indication
18.19.2.4. By End-Users
18.19.2.5. By Application
18.20. South Korea
18.20.1. Pricing Analysis
18.20.2. Market Share Analysis, 2023
18.20.2.1. By Product
18.20.2.2. By Technology
18.20.2.3. By Indication
18.20.2.4. By End-Users
18.20.2.5. By Application
18.21. GCC Countries
18.21.1. Pricing Analysis
18.21.2. Market Share Analysis, 2023
18.21.2.1. By Product
18.21.2.2. By Technology
18.21.2.3. By Indication
18.21.2.4. By End-Users
18.21.2.5. By Application
18.22. South Africa
18.22.1. Pricing Analysis
18.22.2. Market Share Analysis, 2023
18.22.2.1. By Product
18.22.2.2. By Technology
18.22.2.3. By Indication
18.22.2.4. By End-Users
18.22.2.5. By Application
18.23. Israel
18.23.1. Pricing Analysis
18.23.2. Market Share Analysis, 2023
18.23.2.1. By Product
18.23.2.2. By Technology
18.23.2.3. By Indication
18.23.2.4. By End-Users
18.23.2.5. By Application
19. Market Structure Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Market Share Analysis of Top Players
19.3.1. By Regional
19.3.2. By Product
19.3.3. By Technology
19.3.4. By Indication
19.3.5. By End-Users
19.3.6. By Application
20. Competition Analysis
20.1. Competition Deep Dive
20.1.1. AGILENT TECHNOLOGIES
20.1.1.1. Overview
20.1.1.2. Product Portfolio
20.1.1.3. Profitability by Market Segments
20.1.1.4. Sales Footprint
20.1.1.5. Strategy Overview
20.1.1.5.1. Marketing Strategy
20.1.2. Sartorius AG
20.1.2.1. Overview
20.1.2.2. Product Portfolio
20.1.2.3. Profitability by Market Segments
20.1.2.4. Sales Footprint
20.1.2.5. Strategy Overview
20.1.2.5.1. Marketing Strategy
20.1.3. NanoString Technologies
20.1.3.1. Overview
20.1.3.2. Product Portfolio
20.1.3.3. Profitability by Market Segments
20.1.3.4. Sales Footprint
20.1.3.5. Strategy Overview
20.1.3.5.1. Marketing Strategy
20.1.4. THERMO FISHER SCIENTIFIC
20.1.4.1. Overview
20.1.4.2. Product Portfolio
20.1.4.3. Profitability by Market Segments
20.1.4.4. Sales Footprint
20.1.4.5. Strategy Overview
20.1.4.5.1. Marketing Strategy
20.1.5. BIO-RAD LABORATORIES
20.1.5.1. Overview
20.1.5.2. Product Portfolio
20.1.5.3. Profitability by Market Segments
20.1.5.4. Sales Footprint
20.1.5.5. Strategy Overview
20.1.5.5.1. Marketing Strategy
20.1.6. F. HOFFMANN-LA ROCHE LTD.
20.1.6.1. Overview
20.1.6.2. Product Portfolio
20.1.6.3. Profitability by Market Segments
20.1.6.4. Sales Footprint
20.1.6.5. Strategy Overview
20.1.6.5.1. Marketing Strategy
20.1.7. PERKINELMER
20.1.7.1. Overview
20.1.7.2. Product Portfolio
20.1.7.3. Profitability by Market Segments
20.1.7.4. Sales Footprint
20.1.7.5. Strategy Overview
20.1.7.5.1. Marketing Strategy
20.1.8. ILLUMINA
20.1.8.1. Overview
20.1.8.2. Product Portfolio
20.1.8.3. Profitability by Market Segments
20.1.8.4. Sales Footprint
20.1.8.5. Strategy Overview
20.1.8.5.1. Marketing Strategy
20.1.9. QIAGEN N.V.
20.1.9.1. Overview
20.1.9.2. Product Portfolio
20.1.9.3. Profitability by Market Segments
20.1.9.4. Sales Footprint
20.1.9.5. Strategy Overview
20.1.9.5.1. Marketing Strategy
20.1.10. Charles River Laboratories
20.1.10.1. Overview
20.1.10.2. Product Portfolio
20.1.10.3. Profitability by Market Segments
20.1.10.4. Sales Footprint
20.1.10.5. Strategy Overview
20.1.10.5.1. Marketing Strategy
21. Assumptions & Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Immuno Oncology Assay Market
